Advertisement
Mayo Clinic Proceedings Home

New-Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long-Term Survival After Liver Transplant: A Machine Learning Approach

      Abstract

      Objective

      To identify key predictors and survival outcomes of new-onset diabetes after transplant (NODAT) in liver transplant (LT) recipients by using the Scientific Registry of Transplant Recipients.

      Patients and Methods

      Data of all adult LT recipients between October 1, 1987, and March 31, 2016, were analyzed using various machine learning methods. These data were divided into training (70%) and validation (30%) data sets to robustly determine predictors of NODAT. The long-term survival of patients with NODAT relative to transplant recipients with preexisting diabetes and those without diabetes was assessed.

      Results

      Increasing age (odds ratio [OR], 1.01; 95% CI, 1.00-1.02; P≤.001), male sex (OR, 1.09; 95% CI, 1.05-1.13; P=.03), and obesity (OR, 1.13; 95% CI, 1.08-1.18; P<.001) were significantly associated with NODAT. Sirolimus as a primary immunosuppressant carried a 33% higher risk of NODAT than did tacrolimus (OR, 1.33; 95% CI, 1.22-1.45; P<.001) at 1 year after LT. Patients with NODAT had significantly decreased 10-year survival than did those without diabetes (63.0% vs 74.9%; P<.001), similar to survival in patients with diabetes before LT (58.9%).

      Conclusion

      Using a machine learning approach, we found that older, male, and obese recipients are at especially higher risk of NODAT. Donor features do not affect risk. In addition, sirolimus-based immunosuppression is associated with a significantly higher risk of NODAT than other immunosuppressants. Most importantly, NODAT adversely affects long-term survival after LT in a manner similar to preexisting diabetes, indicating the need for more aggressive care and closer follow-up.

      Abbreviations and Acronyms:

      BMI (body mass index), LT (liver transplant), ML (machine learning), mTOR (mammalian target of rapamycin), NODAT (new-onset diabetes after transplant), OR (odds ratio), SRTR (Scientific Registry of Transplant Recipients)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and PersonalCorporate R&D Professionals
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kesiraju S.
        • Paritala P.
        • Rao Ch U.M.
        • Sahariah S.
        New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis.
        Transpl Immunol. 2014; 30: 52-58
        • Watt K.D.
        • Pedersen R.A.
        • Kremers W.K.
        • Heimbach J.K.
        • Charlton M.R.
        Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.
        Am J Transplant. 2010; 10: 1420-1427
        • Ali I.H.
        • Adberrahim E.
        • Ben Abdelghani K.
        • et al.
        Incidence and risk factors for post-renal transplant diabetes mellitus.
        Transplant Proc. 2011; 43: 568-571
        • First M.R.
        • Dhadda S.
        • Croy R.
        • Holman J.
        • Fitzsimmons W.E.
        New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials.
        Transplantation. 2013; 96: 58-64
        • Lv C.
        • Zhang Y.
        • Chen X.
        • et al.
        New-onset diabetes after liver transplantation and its impact on complications and patient survival.
        J Diabetes. 2015; 7: 881-890
        • Van Laecke S.
        • Desideri F.
        • Geerts A.
        • et al.
        Hypomagnesemia and the risk of new-onset diabetes after liver transplantation.
        Liver Transpl. 2010; 16: 1278-1287
        • Charco R.
        • Cantarell C.
        • Vargas V.
        • et al.
        Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
        Liver Transpl Surg. 1999; 5: 204-208
        • Davidson J.A.
        • Wilkinson A.
        • International Expert Panel on New-Onset Diabetes after Transplantation
        New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist’s view.
        Diabetes Care. 2004; 27: 805-812
        • Ojo A.O.
        Cardiovascular complications after renal transplantation and their prevention.
        Transplantation. 2006; 82: 603-611
        • Hjelmesaeth J.
        • Hartmann A.
        • Leivestad T.
        • et al.
        The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events.
        Kidney Int. 2006; 69: 588-595
        • Boudreaux J.P.
        • McHugh L.
        • Canafax D.M.
        • et al.
        The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.
        Transplantation. 1987; 44: 376-381
        • Song J.L.
        • Gao W.
        • Zhong Y.
        • et al.
        Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
        World J Gastroenterol. 2016; 22: 2133-2141
        • Moon J.I.
        • Barbeito R.
        • Faradji R.N.
        • Gaynor J.J.
        • Tzakis A.G.
        Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up.
        Transplantation. 2006; 82: 1625-1628
        • Ling Q.
        • Xu X.
        • Xie H.
        • et al.
        New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry.
        Liver Int. 2016; 36: 705-712
        • Liu F.C.
        • Lin J.R.
        • Chen H.P.
        • Tsai Y.F.
        • Yu H.P.
        Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: a population-based cohort study.
        Medicine (Baltimore). 2016; 95: e3829
        • John P.R.
        • Thuluvath P.J.
        Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus.
        Liver Transpl. 2002; 8: 708-713
        • Yagi S.
        • Kaido T.
        • Iida T.
        • Yoshizawa A.
        • Okajima H.
        • Uemoto S.
        New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function.
        Surg Today. 2017; 47: 733-742
        • Johnston O.
        • Rose C.L.
        • Webster A.C.
        • Gill J.S.
        Sirolimus is associated with new-onset diabetes in kidney transplant recipients.
        J Am Soc Nephrol. 2008; 19: 1411-1418
        • Teutonico A.
        • Schena P.F.
        • Di Paolo S.
        Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
        J Am Soc Nephrol. 2005; 16: 3128-3135
        • Romagnoli J.
        • Citterio F.
        • Nanni G.
        • et al.
        Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
        Transplant Proc. 2006; 38: 1034-1036
        • Deblon N.
        • Bourgoin L.
        • Veyrat-Durebex C.
        • et al.
        Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.
        Br J Pharmacol. 2012; 165: 2325-2340
        • Bhat M.
        • Pasini E.
        • Copeland J.
        • et al.
        Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: a systems biology approach to post-transplant diabetes.
        Sci Rep. 2017; 7: 10277
        • Ling Q.
        • Xie H.
        • Lu D.
        • et al.
        Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population.
        J Hepatol. 2013; 58: 271-277
        • Cosio F.G.
        • Pesavento T.E.
        • Osei K.
        • Henry M.L.
        • Ferguson R.M.
        Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.
        Kidney Int. 2001; 59: 732-737
        • Kasiske B.L.
        • Snyder J.J.
        • Gilbertson D.
        • Matas A.J.
        Diabetes mellitus after kidney transplantation in the United States.
        Am J Transplant. 2003; 3: 178-185